Display Settings:

Format

Send to:

Choose Destination
    Nat Nanotechnol. 2007 Dec;2(12):751-60.

    Nanocarriers as an emerging platform for cancer therapy.

    Source

    Department of Anesthesia, Immune Disease Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

    Abstract

    Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.

    PMID:
    18654426
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk